现实世界中的急性原核细胞白血病:了解结果差异以及我们如何改善它们
Aram Bidikian1, Jan Philipp Bewersdorf2, Tariq Kewan2
1Department of Internal Medicine, Yale School of Medicine, Yale New Haven Hospital, New Haven, CT 06510, USA.
Cancers
|December 17, 2024
概括
在现实世界中,由于患者因素和实践变化,急性肌肉细胞白血病 (APL) 治疗结果落后于临床试验. 改善结果需要加强可测量的残留疾病 (MRD) 的教育,合作和监测.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 临床实践 临床实践
背景情况:
- 全跨视网红酸 (ATRA) 和三氧化 (ATO) 已经改变了急性肌性白血病 (APL) 的治疗方法.
- 对于APL患者来说,现实世界的结果往往不同于临床试验结果,这是由于人口和实践的变化.
- 老年患者和患有并发症的患者在试验中代表性不足,但在临床实践中很常见.
研究的目的:
- 审查现实世界APL治疗结果.
- 为了突出APL集群的现象.
- 确定导致APL护理和结果差异的因素.
主要方法:
- 文献综述,重点关注现实世界APL治疗结果.
- 分析影响患者人口统计和临床实践的因素.
- 检查APL集群发病率和潜在影响.
主要成果:
- 在现实环境中,APL的早期死亡率更高,受到延迟诊断,治疗开始,提供者缺乏经验和资源限制的影响.
- 疾病和诱导相关的并发症显著导致早期死亡率.
- 经常报告APL群体,但人们对其了解甚少.
结论:
- 加强社区和专家中心之间的教育和合作对于改善APL结果至关重要.
- 国际伙伴关系可以使资源有限的环境受益.
- 持续监测可测量的残留疾病 (MRD),治疗毒性以及了解APL集群对于未来的管理和资源分配至关重要.
关键词:
急性促细胞白血病 (APL) 是一种严重的疾病.全跨网红酸 (ATRA) 的使用.三氧化物 (ATO) 是一种临床试验是指临床试验中的临床试验.集群集群是指一个集群的集群.差异化综合征是什么现实世界的结果.幸存率 幸存率 生存率更多相关视频
10:18From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia
Published on: October 19, 2014
13.7K
09:01Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
Published on: March 26, 2018
13.9K
相关概念视频
Bone Marrow Sampling and Transplants
282
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
282
Cancer Survival Analysis
328
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
328
Disorders of Leukocytes
851
Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
851
